Leerink Partners Maintains Outperform on United Therapeutics, Raises Price Target to $725

Leerink Partners analyst Roanna Ruiz has maintained an 'Outperform' rating on United Therapeutics (NASDAQ: UTHR) and increased the price target from $685 to $725.